A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2002
12/19/2002	WO2002100413A1 A PHARMACEUTICAL COMBINATION COMPRISING EITHER (S)-2-ETHOXY-3- [4-(2-{4-METHANE SULFONYL OXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID OR 3-{4-[2-(4-TERT- BUTOXY CARBONYL AMINOPHENYL) ETHOXY] PHENYL} -(s)-2-ETHOXY PROPANOIC ACID AND A SULONYLUREA
12/19/2002	WO2002100412A2 Stabilized dispersion of phytosterol in oil
12/19/2002	WO2002100408A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
12/19/2002	WO2002100405A1 Isoquinoline inhibitors of p38
12/19/2002	WO2002100403A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	WO2002100400A1 Organic nitrate-based compounds for the treatment of vasculopathies
12/19/2002	WO2002100398A1 Combination of a ptpase inhibitor and an ace inhibitor
12/19/2002	WO2002100397A1 COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
12/19/2002	WO2002100396A1 COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
12/19/2002	WO2002100354A2 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
12/19/2002	WO2002100341A2 Compounds for the treatment of metabolic disorders
12/19/2002	WO2002100332A2 Isoxazoline compounds having mif antagonist activity
12/19/2002	WO2002100330A2 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
12/19/2002	WO2002100328A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	WO2002100323A2 METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS
12/19/2002	WO2002100193A1 Body temperature-raising agent of amino acids for eating or drinking and for medical use
12/19/2002	WO2002100148A2 Treatment or prophylaxis of insulin-producing cell graft rejection
12/19/2002	WO2002088144A3 ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-f]QUINOXALINE
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002064755A3 Post-partum mammalian placenta, its use and placental stem cells therefrom
12/19/2002	WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002	WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002	WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002	WO2002053106A3 Autoantigen composition
12/19/2002	WO2002024727A3 New inhibitors of iapp fibril formation and uses thereof
12/19/2002	WO2002005795A3 Pharmaceutical combinations for treatment and prevention of diabetes mellitus
12/19/2002	WO2001072977A9 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
12/19/2002	US20020193634 Disulfide derivatives useful for treating allergic diseases
12/19/2002	US20020193633 Mast cell stabilizers
12/19/2002	US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002	US20020193595 Agonists of the melanocortin-4 receptor ("MC-4r"); useful treating obesity and type 2 diabetes
12/19/2002	US20020193571 Wsx receptor agonist antibodies
12/19/2002	US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002	US20020193406 Novel compound
12/19/2002	US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002	US20020193403 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
12/19/2002	US20020193357 Liver X receptor agonists
12/19/2002	US20020193344 Acid controlled induced viscosity fiber system and uses thereof
12/19/2002	US20020193315 Having inhibitory activity against diacylglycerol acyltransferase and useful for therapy and prophylaxid of disease of humans such as obesity or hyperlipidemia which is caused by accumulation of triacylglycerol
12/19/2002	US20020193310 For therapy of hyperglycemic disorders
12/19/2002	US20020192816 Human pancreatic progenitor cells for use in cell therapy
12/19/2002	US20020192770 Beta-glucan products and extraction processes from cereals
12/19/2002	US20020192758 C3b/C4b complement receptor-like molecules and uses thereof
12/19/2002	US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002	US20020192737 Detecting modulators of oxidoreductases; obtain sample, incubate with modulator, detect signal, monitor adjustment in enzyme activity
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192354 Calorically dense liquid oral supplement
12/19/2002	US20020192334 Method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby
12/19/2002	US20020192285 Controlled release pellet formulation
12/19/2002	US20020192282 Multilayer pharmaceutical product for release in the colon
12/19/2002	US20020192264 Materials and methods for the treatment or prevention of obesity
12/19/2002	US20020192235 Novel vitamin b12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
12/19/2002	US20020192203 Sterol absorption inhibitor compositions
12/19/2002	US20020192164 Methods and compositions for the pulmonary delivery insulin
12/19/2002	DE10127897A1 Combined pharmaceutical formulation for treating osteoporosis or related disorders, comprising core of dried plant extract enclosed in sheath of calcium salt
12/19/2002	CA2450617A1 Methyl analogs of simvastatin as novel hmg-coa reductase inhibitors
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449654A1 Methods for treating disorders of the nervous and reproductive systems
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449602A1 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
12/19/2002	CA2449256A1 Modulators of peroxisome proliferator activated receptors
12/19/2002	CA2448763A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert- butoxy carbonyl aminophenyl)ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
12/19/2002	CA2448552A1 Modulators of peroxisome proliferator activated receptors (ppar)
12/19/2002	CA2447658A1 Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines
12/19/2002	CA2447557A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	CA2446223A1 Stabilized dispersion of phytosterol in oil
12/19/2002	CA2445653A1 Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
12/19/2002	CA2445605A1 Treatment or prophylaxis of insulin-producing cell graft rejection
12/19/2002	CA2445467A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1266897A2 Hypoglycemic imidazoline compounds
12/18/2002	EP1266896A1 Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266888A1 Quinoline derivatives and medicinal use thereof
12/18/2002	EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002	EP1266012A2 Proteases
12/18/2002	EP1266010A2 Genetically modified plants and plant cells comprising heterologous heavy metal transport and complexation proteins
12/18/2002	EP1266001A2 Human transcription factors
12/18/2002	EP1265989A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
12/18/2002	EP1265985A1 Pancreatic islet cell growth factors
12/18/2002	EP1265942A2 Use of poly(diallylamine) polymers
12/18/2002	EP1265922A2 Agonists and antagonists of the receptor gpr19 and their use in appetite control
12/18/2002	EP1265919A2 G-protein associated molecules
12/18/2002	EP1265913A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
12/18/2002	EP1265907A2 Novel aryl fructose-1,6-bisphosphatase inhibitors
12/18/2002	EP1265900A1 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
12/18/2002	EP1265899A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/18/2002	EP1265893A1 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
12/18/2002	EP1265891A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
12/18/2002	EP1265860A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
12/18/2002	EP1265859A2 Amidino compounds useful as nitric oxide synthase inhibitors
12/18/2002	EP1265848A2 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
12/18/2002	EP1265840A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
12/18/2002	EP1265839A1 Compounds active at the glucocorticoid receptor
12/18/2002	EP1265838A1 Novel fatty acid analogous
12/18/2002	EP1265638A1 Compositions for transdermal and transmucosal administration of therapeutic agents
12/18/2002	EP1265629A1 Use of growth hormone in low dose
12/18/2002	EP1265628A1 Use of human not1 and not1a orphan receptors

1 ... 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 ... 1298